pathway polymorphisms have been the most widely reported pharmacological pathway influencing bupropion efficacy for smoking cessation in retrospective analyses of clinical trials (12, 13, 21). In addition, the AGES formula applied equal weights to each polymorphism as a default, counted efficacy alleles for each polymorphism and assumed linear influence for each additional allele based on an additive model assumption, tallied the additive effects across the variants which does not allow for possible interactive effects across different variants (i.e., epistasis), and was limited in candidate gene selection.
